

Innovative BioMedical Devices

ABN 35 088 221 078

bioMD Limited

Level 11, 225 St Georges Terrace

Perth, Western Australia 6000

PO Box 7209, Cloisters Square

Western Australia 6850

Telephone (08) 9262 6777

Facsimile (08) 9322 3433

ABN 35 088 221 078

www.biomd.com.au

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 2 pages

9 November 2009

AUSTRALIAN CLINICAL TRIAL

PERTH Australia: bioMD Limited (ASX:BOD) announces that its subsidiary, Celxcel Pty Ltd, has successfully implanted 2 patients with its "Gynecel" ADAPT® treated biomaterial patch in the Phase II clinical trial for pelvic floor reconstruction surgery.

These 2 implants represent the first of 20 patients to be implanted with the Gynecel in post-menopausal women requiring surgery for vaginal prolapse. The study is being conducted within St George Hospital Sydney and the surgical team, who are all members of the Sydney Women's Endosurgery Centre (SWEC), is being led by Dr Gregory Cario.

When the study was approved in late August, Dr Cario stated:

"We have been impressed by the extensive pre-clinical studies conducted with this material and are encouraged by the results from the recent cardiovascular study in children."

Both the current study in pelvic floor repair and the paediatric cardiovascular study (soon to be published) have both been initiated to support a broader commercial business model for the ADAPT treated biomaterial patch. Mr Michael Bennett, Managing Director of bioMD, said:

"These two studies will provide us with a solid platform from which we can generate our next-stage products for use by a broader surgical population, both here in Australia as well as overseas."

The St George study is projected to have all 20 patients implanted towards the end of Q1 2010 and any interim results of both 6 week and 6 month follow-up data will be reported around that time.

About BioMD Limited

bioMD (ASX: BOD) is an Australian company commercialising innovative tissue engineering technology for use in cardiothoracic and abdominal surgery. The ADAPT technology offers significant improvements to current tissue processing technologies in terms of immunogenicity and tissue durability. Its lead product, CardioCel, continues to be evaluated in a Phase II human trial in South Africa for various cardiac repair procedures. bioMD is currently maximising shareholder value via pursuit of corporate partnerships, successful completion of clinical milestones and rapid commercialisation strategies.

About the ADAPT® Tissue Engineering Process

The ADAPT Tissue Engineered Process (TEP), developed by Celxcel Pty Ltd, a subsidiary of bioMD, produces a bioprosthetic scaffold (extracellular matrix) made from animal tissue. Depending on the site of implantation, the patient's own cells will migrate into the matrix and stimulate site specific controlled remodelling. At the same time, new blood vessels are formed in the matrix and they deliver appropriate cells that lead to a functional tissue repair. The implanted extracellular matrix is gradually remodelled and replaced by the body's own new tissue structures.